GLZ MEX 60mg/500mg Tablet is a combination oral hypoglycemic agent containing Gliclazide 60mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. This dual mechanism addresses hyperglycemia through complementary pathways, making GLZ MEX effective in patients inadequately controlled by diet and exercise alone. The tablet is prescribed as part of a comprehensive diabetes management plan including lifestyle modification. It is essential to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to lactic acidosis, a rare but serious adverse effect associated with Metformin. Contraindications include type 1 diabetes, diabetic ketoacidosis, and known hypersensitivity to either component. Common side effects may include gastrointestinal disturbances and hypoglycemia. GLZ MEX 60mg/500mg Tablet should be used under medical supervision with periodic assessment of glycemic control and overall patient status.